Lonza's virus factory shows gene therapy's Texas-sized promise

ZURICH (Reuters) - Swiss drugmaker-for-hire Lonza is betting that trillions of customized viruses made at a giant factory in Texas will be the lucrative raw materials of a medical revolution.

Mylan to buy MS drug marketing rights from Israel's Mapi Pharma

(Reuters) - Mylan NV will buy global marketing rights to an experimental multiple sclerosis treatment from Israel's Mapi Pharma, aiming to strengthen its position in the market for MS drugs and counter falling sales of its emergency allergy shot EpiPen.

New GSK shingles vaccine off to strong start in key U.S. market

LONDON (Reuters) - GlaxoSmithKline's new shingles vaccine - a priority product as the company strives to improve its drugs line-up - has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show.

Loxo, Illumina to partner for diagnostic tool targeting cancer

(Reuters) - Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

FDA needs more time to review AbbVie, Neurocrine's uterine pain drug

(Reuters) - AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug.

Researchers propose new Alzheimer's definition based on biology

(Reuters) - Alzheimer's researchers have proposed a radical change in the way the disease is defined, focusing on biological changes in the body rather than clinical symptoms such as memory loss and cognitive decline.

Costs of 'informal' caregiving for heart disease to reach $128 billion by 2035

(Reuters Health) - As relatives and friends step in to provide increasingly complex care at home for heart attack and stroke survivors, the costs associated with such "informal" caregiving are expected to double to $128 billion by 2035, U.S. heart doctors say.

New device would allow blood-free monitoring of blood sugar levels

(Reuters Health) - A new device applied to the skin could allow people with diabetes to monitor their blood sugar levels without the need for finger sticks or other blood sampling.

Using transgender youths' chosen names may lower suicide risk

(Reuters Health) - When a transgender youth chooses a new name, it's important for friends, relatives and acquaintances to use that chosen name, a new study suggests.

When heart disease runs in the family, exercise tied to lower risk

(Reuters Health) - People who get plenty of exercise are less likely to have heart attacks and strokes than their inactive counterparts, even when they have a genetic predisposition for heart disease, a U.K. study suggests.

Related Videos

Island of plastic garbage in Pacific 16 times bigger than thought - study

'Roseanne' star says revived show reflects Trump's America

Read Reuters on the go

Download the free Reuters News app today for breaking news, analysis and market data from the world's most trusted news organization.

Get the app